Trinity Biotech (TRIB) Short term Debt (2022 - 2024)

Trinity Biotech has disclosed Short term Debt across 3 years of filings, most recently posting $1.7 million for Q4 2024.

• Short term Debt for Q4 2024 came in at $1.7 million, up 215.21% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.7 million (up 215.21% YoY), and the FY2024 annual result was $1.7 million, up 215.21% from the prior year.
• Short term Debt came in at $1.7 million for Q4 2024 at Trinity Biotech, up from $596000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $2.0 million in Q2 2022 to a low of $526000.0 in Q4 2023.
• The 3-year median for Short term Debt is $1.5 million (2023), against an average of $1.4 million.
• Across the five-year window, Short term Debt slumped 66.48% in 2023 and jumped 215.21% in 2024, its largest moves.
• Trinity Biotech's Short term Debt stood at $1.6 million in 2022, then plunged by 66.48% to $526000.0 in 2023, then surged by 215.21% to $1.7 million in 2024.
• The last three Short term Debt figures came in at $1.7 million (Q4 2024), $596000.0 (Q3 2024), and $1.4 million (Q2 2024), per Business Quant data.